Full text is available at the source.
Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation
Tirzepatide does not change metabolism adjustment in obesity but increases fat burning
AI simplified
Abstract
Tirzepatide promoted significant body weight reduction in phase 3 clinical trials.
- In calorie-restricted, obese mice, chronic tirzepatide treatment reduced the drop in energy expenditure compared to vehicle-treated and pair-fed mice.
- Tirzepatide treatment was associated with increased fat oxidation as indicated by a decrease in the respiratory exchange ratio in mice.
- In a phase 1 clinical trial, tirzepatide led to increased fat oxidation and reductions in appetite and calorie intake during an ad libitum test meal compared to placebo.
- Chronic treatment with tirzepatide did not appear to impact metabolic adaptation in the clinical trial.
AI simplified